This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignee: University System of Maryland. Active years: 2007-2011.
Company Filing History:
Years Active: 2007-2011
Title: John C McLenithan: Innovator in Disease Diagnosis and Treatment
Introduction
John C McLenithan is a notable inventor based in Baltimore, MD (US). He has made significant contributions to the field of medical diagnostics and treatment, holding a total of 3 patents. His work focuses on innovative methods for diagnosing diseases and modifying glucose activity, which have the potential to impact healthcare positively.
Latest Patents
One of McLenithan's latest patents is titled "Method of diagnosing or predicting disease states in a subject using omentin 1 and omentin 2." This invention is directed towards diagnosing diseases such as obesity, cardiovascular disease, and metabolic disorders by analyzing the levels of omentin 1 and 2 proteins in subjects. Additionally, it includes methods for treating diseases using these proteins.
Another significant patent is "Method of modifying glucose activity using polypeptides selectively expressed in fat tissue." This invention involves isolated omentin polypeptides that can modify insulin action and glucose metabolism in animals. The polypeptides are designed to promote glucose uptake in adipocytes and can be utilized in diagnostic tests for diseases related to glucose metabolism.
Career Highlights
John C McLenithan is affiliated with the University System of Maryland, where he continues to advance his research and innovations. His work has garnered attention for its potential applications in treating metabolic diseases and improving diagnostic methods.
Collaborations
Some of McLenithan's notable coworkers include Da-Wei Gong and Alan R Shuldiner. Their collaborative efforts contribute to the ongoing research and development in the field of medical science.
Conclusion
John C McLenithan's innovative work in disease diagnosis and treatment exemplifies the impact of research on healthcare. His patents reflect a commitment to advancing medical science and improving patient outcomes.